Literature DB >> 26815213

Patient selection criteria for primary total hip Arthroplasty in displaced intracapsular hip fractures: Are they appropriate?

Muhammad E A Khan1, Sanju Mathew1, Syazrah Salam1, Sally Lambert2, James D Price3, Keith M Willett4.   

Abstract

INTRODUCTION: This study aims to determine, by outcome analysis, the appropriateness of current criteria employed to select patients for total hip arthroplasty (THA) as the primary treatment for displaced intracapsular hip fracture (DICHF). This study is intended to inform prospective randomised controlled trials investigating the efficacy of THA as a primary treatment.
MATERIALS AND METHODS: Contemporary THA eligibility criteria were derived from recent publications relating to pre-fracture residence, mobility and independence. Outcome data were analysed for 96 patients (19% of 506 consecutive patients with DICHF between March 2003 and February 2005) who fulfilled those criteria. The variables analysed included age, gender, co-existing injuries, co-morbidities, social circumstances, mobility, independence, delay to surgery, readmission and death. The 96 patients included in the study were followed for 3 years. The primary outcome was the combined achievement of home or warden-assisted accommodation at 3 months, no patient readmission within 6 weeks of discharge and survival to 1 year. Secondary outcome was survival to 3 years.
RESULTS: At 3 months, 86 patients (90%) had returned home, three (3.1%) required nursing or residential home placement, four (4.2%) were still resident in a community hospital and three (3.1%) had died. A total of ten patients failed to return to their own home. Eight patients (8.3%) were readmitted within 6 weeks. At 1 year, eight patients (8.3%) had died; by 3 years, the mortality rate was 25%. Patients not achieving return to home were older (84.8 years vs. 79.7 years, p = 0.19), prior to fracture weremore likely to use a walking aid (odds ratio [OR] 2.35) or required home support (OR 1.74). The number of co-morbidities was not an association. Backward selection applied to the above data produced an OR of 1.12 (confidence interval [CI] 1.01-1.21) for age as a variable in patients successfully discharged home, so that for each increase in age by year, the odds of home not being the final destination increased by 12%. These factors were also reflected in the patients requiring readmission within 6 weeks from discharge.
CONCLUSIONS: If maintaining a high level of activity and independence is the expectation in patients considered for THA for DICHFs, then current selection criteria appear to be appropriate in identifying those capable of returning home, remaining independent and surviving to 1 year compared to the whole DICHF population. With a 75% 3-year survival, the postulated benefit of THA will not be realised in many patients and this needs to be considered. Cost-effectiveness trials are required before broad practice change occurs.

Entities:  

Keywords:  Arthroplasty; Hip fracture; Intracapsular; Outcome; Subcapital

Year:  2009        PMID: 26815213     DOI: 10.1007/s00068-009-8222-1

Source DB:  PubMed          Journal:  Eur J Trauma Emerg Surg        ISSN: 1863-9933            Impact factor:   3.693


  18 in total

1.  Internal fixation versus hemiarthroplasty versus total hip arthroplasty for displaced subcapital fractures of femur--13 year results of a prospective randomised study.

Authors:  K J Ravikumar; G Marsh
Journal:  Injury       Date:  2000-12       Impact factor: 2.586

2.  Displaced intracapsular hip fractures in fit, older people: a randomised comparison of reduction and fixation, bipolar hemiarthroplasty and total hip arthroplasty.

Authors:  J F Keating; A Grant; M Masson; N W Scott; J F Forbes
Journal:  Health Technol Assess       Date:  2005-10       Impact factor: 4.014

3.  Factors affecting ambulatory status and survival of patients 90 years and older with hip fractures.

Authors:  Yoichiro Ishida; Shinya Kawai; Toshihiko Taguchi
Journal:  Clin Orthop Relat Res       Date:  2005-07       Impact factor: 4.176

4.  Comparison of internal fixation with total hip replacement for displaced femoral neck fractures. Randomized, controlled trial performed at four years.

Authors:  Richard Blomfeldt; Hans Törnkvist; Sari Ponzer; Anita Söderqvist; Jan Tidermark
Journal:  J Bone Joint Surg Am       Date:  2005-08       Impact factor: 5.284

5.  Evaluation of a mental test score for assessment of mental impairment in the elderly.

Authors:  H M Hodkinson
Journal:  Age Ageing       Date:  1972-11       Impact factor: 10.668

6.  Total hip arthroplasty and hemiarthroplasty in mobile, independent patients with a displaced intracapsular fracture of the femoral neck. A randomized, controlled trial.

Authors:  R P Baker; B Squires; M F Gargan; G C Bannister
Journal:  J Bone Joint Surg Am       Date:  2006-12       Impact factor: 5.284

7.  Randomized comparison of reduction and fixation, bipolar hemiarthroplasty, and total hip arthroplasty. Treatment of displaced intracapsular hip fractures in healthy older patients.

Authors:  J F Keating; A Grant; M Masson; N W Scott; J F Forbes
Journal:  J Bone Joint Surg Am       Date:  2006-02       Impact factor: 5.284

8.  A randomised controlled trial comparing bipolar hemiarthroplasty with total hip replacement for displaced intracapsular fractures of the femoral neck in elderly patients.

Authors:  R Blomfeldt; H Törnkvist; K Eriksson; A Söderqvist; S Ponzer; J Tidermark
Journal:  J Bone Joint Surg Br       Date:  2007-02

9.  Functional outcomes and mortality vary among different types of hip fractures: a function of patient characteristics.

Authors:  Roger Cornwall; Marvin S Gilbert; Kenneth J Koval; Elton Strauss; Albert L Siu
Journal:  Clin Orthop Relat Res       Date:  2004-08       Impact factor: 4.176

10.  Functional outcome and quality of life following hip fracture in elderly women: a prospective controlled study.

Authors:  Steven Boonen; Philippe Autier; Martine Barette; Dirk Vanderschueren; Paul Lips; Patrick Haentjens
Journal:  Osteoporos Int       Date:  2003-11-07       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.